

SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools

Coordination, management,
dissemination and training
WP6 aims at:
-
Securing and implementing proper project
coordination and management as well as
monitoring of project progress.
-
Ensuring compliance with the reporting procedures set out by IMI
-
Fostering communication within the SUMMIT and with external stakeholders, e.g. the scientific communities, regulatory bodies, health care professionals, IMI, and EC
-
Disseminating the project’s research results to scientific and non-specialist audiences in a comprehensive way
-
Organizing training activities for young scientists from academia and pharmaceutical industry related to the SUMMIT research area of diabetic complications
Work Package 6 (WP6)
Participants
The SUMMIT governance structure includes the Executive Board, the Steering Committee and the Plenum. The Steering Committe consults on a regular basis with Scientific Advisory Board and provides its scientific expertise to the consortium.
Members of the Executive Board are:
Together they take responsibility for the day-to-day monitoring of the project and proper implementation of the decisions of the Steering Committee.
The Steering Committee consists of the members of the Executive Board and work package leaders from all work packages, one from EFPIA and one from academia each. The representation of all work packages will insure good information sharing across the various work packages. The Steering committee takes strategic decisions.
The Plenum provides scientific expertise and reviews the project on a regular basis.
MISSION
To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
-
the identification of patients at high risk of diabetes complications
-
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.